Literature DB >> 17978735

[Empiric antituberculous therapy in patients with unexplained exsudative pleural effusion. Is it valid in Senegal?].

M Sané1, K Ba-Fall, N Lefebvre, D Mounguengui, P Camara, A Niang, A Bonnichon, B Chevalier, P Saliou-Mbaye, J-M Debonne, J Margery.   

Abstract

AIM: Pleural biopsy and adenosine deaminase activity are not available at our center and the treatment begins without substantiation diagnosis in patients with tuberculous pleural effusion (PE).
METHODS: In order to evaluate the validity of an empiric antituberculous therapy in exsudative PE with high prevalence of lymphocytes, we conducted a retrospective study during 1 year. Patient was enrolled if no signs of tuberculous infection, pneumonia or cancer were present.
RESULTS: During 1 year, 38 patients were enrolled (23 males, mean age=36 years). PE was major (> 2/3 of the lung) in 14 cases, moderate (between 1/3 and 2/3) In 18 cases and minor (<1/3) in 6 cases. Tuberculous contagion was observed in 10 patients. Tuberculinic test was positive in all patients (12-24 mm). Clinical and radiological cure was obtained in 37 cases, except 1 patient who died from acute heart failure. No recurrence of PE was observed after 1 year follow-up.
CONCLUSION: In our endemic areas, empiric antituberculous treatment seems to be an effective strategy in patients with exsudative PE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17978735     DOI: 10.1016/s0761-8417(07)92647-4

Source DB:  PubMed          Journal:  Rev Pneumol Clin        ISSN: 0761-8417


  1 in total

1.  Hyporexia and cellular/biochemical characteristics of pleural fluid as predictive variables on a model for pleural tuberculosis diagnosis.

Authors:  Ana Paula Santos; Marcelo Ribeiro-Alves; Raquel Corrêa; Isabelle Lopes; Mariana Almeida Silva; Thiago Thomaz Mafort; Janaina Leung; Luciana Silva Rodrigues; Rogério Rufino
Journal:  J Bras Pneumol       Date:  2021-12-13       Impact factor: 2.624

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.